References
[1] Al-Hajj, M., Wicha, M. S., Benito-Hernandezt, A., Morrison, S. J., Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. PNAS, 100(7): 3983-88.
[2] Hassan, B. A., Yusoff, Z. (2011). Negative Impact of Chemotherapy on Breast Cancer Patients QOL—Utility of Antiemetic Treatment Guidelines and the Role of Race. Asian Pacific J Cancer Prev, 1523-1527.
[3] Russell, C. A. (2014). Personalized medicine for breast cancer: it is a new day! Am J Surg, 207: 321-5.
[4] Gaudet, M. M., Press, M. F., Haile, R. W., Lynch, C. F., Glaser, S. L., Schildkraut, J., Gammon, M. D., Douglas Thompson, W., Bernstein, J. L. (2011). Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat., 130(2): 587-597.
[5] Marshall, J. C., Collins, J. W., Nakayama, J., Horak, C. E., Liewehir, H. J., Steinberg, S. M., Albaugh, M., Vidal-Vanaclocha, F., Palmieri, D., Barbier, M., Murone, M., Steeg, P. S. (2012). Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst., 104(17): 1306-19.
[6] Bernstein, L., Lacey, J. V. Jr. (2011). Receptors, associations and risk factor differences by breast cancer subtypes: positive or negative? J Natl Cancer Inst., 103: 451-453.
[7] Boyle, P. (2012). Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 23 Suppl 6: vi7-vi12.
[8] Hudis, C. A. (2011). Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist, 16: 1-11.
[9] Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., Pavletich, N. P. (2013). mTOR kinase structure, mechanism and regulation. Nature, 497: 217-23.
[10] Shaw, R. J., Cantley, L. C. (2006). Ras, PI(3)K, and mTOR signalling controls tumor cell growth. Nature, 441: 424-30.
[11] Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., Evers, B. M. (2012). mTOR inhibitors in cancer therapy. Cancer Letters, 319: 1-7.
[12] Yu, K., Toral-Barza, L. (2012). Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor. Methods Mol Biol, 821: 15-28.
[13] Maguire, O., Tornatore, K. M., O'Loughlin, K. L., Venuto, R. C., Minderman, H. (2013). Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A, 83: 1096-104.
[14] Augusto, J. F., Subra, J. F., Onno, C., Villemain, F., Croue, A., Dussaussoy, C., Picquet, J., Coeffic, B., Sayegh, J. (2013). Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. Ann Transplant, 18: 368-77.
[15] Siamakpour-Reihani, S., Caster, J., Bandhu, Nepal, D., Courtwright, A., Hilliard, E., Usary, J., Ketelsen, D., Darr, D., Shen, X. J., Patterson, C., Klauber-Demore, N. (2011). The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS One, 2011, 6(6): e20412.
[16] Jeong, I. J., Lee, S. G., Kim, Y. H., Ko, B. S., Lee, J. W., Son, B. H., Ahn, S. H., Kim, H. J. (2017). Characteristics and prognosis of breast cancer after liver or kidney transplantation. Breast Cancer Res Treat, https://doi.org/10.1007/s10549-017-4504-1.
[17] Sendur, M. A., Zengin, N., Aksoy, S., Altundag, K. (2014). Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin., 30(1): 75-87.
[18] Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., Albarracin, C., Litton, J. K., Chavez-MacGregor, M., Ibrahim, N. K., Murray, J. L. 3rd, Koenig, K. B., Hong, D., Subbiah, V., Kurzrock, R., Janku, F., Moulder, S. L. (2017). Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol., 3: 509-515.